Trials / Completed
CompletedNCT05765773
An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) for Adults Aged 60 Years and Older
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products · Other Government
- Sex
- All
- Age
- 60 Years – 99 Years
- Healthy volunteers
- Accepted
Summary
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products" for Adults Aged 60 Years and Older
Detailed description
An open comparative multicenter prospective study with retrospective data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI "Chumakov FSC R&D IBP RAS" | 200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml. |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2022-10-01
- Completion
- 2023-05-19
- First posted
- 2023-03-13
- Last updated
- 2026-03-19
Locations
7 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT05765773. Inclusion in this directory is not an endorsement.